Canada’s Drug Agency (CDA-AMC) Symposium 2024 is a 3-day hybrid event in Ottawa (ON) that gathers leaders from across Canada with expertise in policy, industry, health technology assessment, patient advocacy, medicine, public health, and communications. Representing Myeloma Canada were Martine Elias – CEO; Jessy Ranger – Director, Health Policy, Advocacy & Patient Services; and Aidan Robertson – Advisor, Health Policy & Advocacy.

In addition to taking part in the 3-day event for producers and users of evidence-based information on drugs and health technologies, Jessy presented the poster, A Canadian Best Practice example of Patient Group-informed Quantitative Preference Study Design exploring Patient, Caregiver and Health Care Professional (HCP) Perspectives in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). The study was co-authored by Bonnie Macfarlane, Richard K Plante, Kun Shi, and Stephanie Soltys of Janssen Inc., and Martine Elias and Jessy Ranger of Myeloma Canada.

Jessy also participated as one of the panelists in panel session #12, Advancing Patient Engagement & Impact in CDA’s Deliberative Process: A Multi-Stakeholder Collaboration along with Gail Attara from GI Society, Nancy Zorzi from Mood Disorders Society of Canada, Bonnie Macfarlane from Janssen Inc., and Nicole Mittman from CDA-AMC. Barry Stein from Colorectal Cancer Canada and Susi Vander Wyk from Cure SMA were equally part of this important collaboration.

These projects have been in the pipeline for many years, and we’re proud to see them come to fruition. We were delighted to take part in this exceptional forum which enabled productive discussions and valuable information sharing. It was a unique opportunity to learn from local, national and international experts who shared their expertise and knowledge.